RU2017121002A - Ингибиторы CD38 и способы лечения - Google Patents

Ингибиторы CD38 и способы лечения Download PDF

Info

Publication number
RU2017121002A
RU2017121002A RU2017121002A RU2017121002A RU2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A
Authority
RU
Russia
Prior art keywords
alkyl
compound
compound according
disease
portions
Prior art date
Application number
RU2017121002A
Other languages
English (en)
Russian (ru)
Other versions
RU2017121002A3 (enExample
Inventor
Дж. Дэвид БЕЧЕРЕР
Родолфо КАДИЛЛА
Дэвид Норман Дитон
Курт ХАФФНЕР
Брэд Ричард Хенке
Фрэнк ПРОЙГШАТ
Кристи ШУЛЬТЕ
Original Assignee
ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед filed Critical ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед
Publication of RU2017121002A publication Critical patent/RU2017121002A/ru
Publication of RU2017121002A3 publication Critical patent/RU2017121002A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2017121002A 2014-12-03 2015-11-19 Ингибиторы CD38 и способы лечения RU2017121002A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086844P 2014-12-03 2014-12-03
US62/086,844 2014-12-03
PCT/IB2015/058965 WO2016087975A1 (en) 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment

Publications (2)

Publication Number Publication Date
RU2017121002A true RU2017121002A (ru) 2019-01-11
RU2017121002A3 RU2017121002A3 (enExample) 2019-03-15

Family

ID=54708091

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017121002A RU2017121002A (ru) 2014-12-03 2015-11-19 Ингибиторы CD38 и способы лечения

Country Status (11)

Country Link
US (1) US9840496B2 (enExample)
EP (1) EP3227275B1 (enExample)
JP (1) JP6550132B2 (enExample)
KR (1) KR20170090478A (enExample)
CN (1) CN107428733A (enExample)
AU (1) AU2015356721B2 (enExample)
BR (1) BR112017011642A2 (enExample)
CA (1) CA2969178A1 (enExample)
ES (1) ES2717260T3 (enExample)
RU (1) RU2017121002A (enExample)
WO (1) WO2016087975A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3544612A4 (en) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
US11535621B2 (en) * 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
US20230025807A1 (en) * 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
KR20230051425A (ko) * 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제
IL301991A (en) * 2020-10-09 2023-06-01 Napa Therapeutics Ltd Heteroaryl amide inhibitors for CD38
EP4263524A1 (en) 2020-12-21 2023-10-25 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators
AR124718A1 (es) 2021-01-29 2023-04-26 Ribon Therapeutics Inc Quinolinas y azaquinolinas como inhibidores de cd38
EP4288053A4 (en) 2021-02-08 2024-12-18 Ohio State Innovation Foundation Small molecule inhibitors of cd38 as immunosuppressants
CN117715897A (zh) * 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途
US20230116972A1 (en) * 2021-07-12 2023-04-20 Cytokinetics, Inc. Cd38 modulators and methods of use thereof
EP4724430A1 (en) * 2023-06-07 2026-04-15 Flagship Pioneering Innovations VI, LLC Condensed azines as inhibitors of cyclic adp ribose hydrolase
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026090190A1 (en) * 2024-10-22 2026-04-30 Aeovian Pharmaceuticals, Inc. Cd38 modulators and uses thereof
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1370139A4 (en) * 2001-01-04 2010-09-22 Einstein Coll Med INHIBITORS OF ADP-RIBOSYLTRANSFERASES, CYCLASES AND HYDROLASES AND THEIR USE
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
WO2010025235A1 (en) * 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
EP2801573A1 (en) * 2013-05-09 2014-11-12 Sanofi Hydantoine derivatives as CD38 inhibitors

Also Published As

Publication number Publication date
BR112017011642A2 (pt) 2018-03-06
US20170260164A1 (en) 2017-09-14
EP3227275A1 (en) 2017-10-11
WO2016087975A1 (en) 2016-06-09
RU2017121002A3 (enExample) 2019-03-15
ES2717260T3 (es) 2019-06-20
AU2015356721B2 (en) 2018-03-15
AU2015356721A1 (en) 2017-06-08
CA2969178A1 (en) 2016-06-09
US9840496B2 (en) 2017-12-12
EP3227275B1 (en) 2019-01-02
CN107428733A (zh) 2017-12-01
JP2018501215A (ja) 2018-01-18
JP6550132B2 (ja) 2019-07-24
KR20170090478A (ko) 2017-08-07

Similar Documents

Publication Publication Date Title
JP2018501215A5 (enExample)
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
EA201791304A1 (ru) Производные изохинолина для лечения вич
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PE20161475A1 (es) Pirazolopiridinas y pirazolopirimidinas
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
EA033061B1 (ru) Спироциклогептаны как ингибиторы rock
EA201691629A1 (ru) Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
RU2016150410A (ru) Ингибиторы фактора xia
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
JP2017514910A5 (enExample)
PH12017501598B1 (en) ß-D-2`-DEOXY-2`a-FLUORO-2`-ß-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
JP2015532645A5 (enExample)
EA201790343A1 (ru) Способ получения сульфамидных производных пиримидина
EA201391629A1 (ru) Ингибиторы цсж-1r для лечения опухолей головного мозга
JP2017517512A5 (enExample)
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
RU2018113718A (ru) Новые соединения
EA201690879A1 (ru) Новое триазолопиридиновое соединение
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
RU2018101431A (ru) Ингибиторы индоламин-2,3-диоксигеназы

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190701